Trump revives plan for IRP use in US via MFN executive order
Trump’s MFN EO aims to secure US drug prices that are the lowest among the reference countries.
Pricing and Market Access
Next-generation targeting for evolving HCP engagement
Pharma faces 30-day deadline under Trump’s pricing order
Trump to sign order tying US drug prices to global rates
5EU Q1 2024 versus 2025: Pricing shifts, HTA outcomes, and innovative drug trends
First two medicinal products to undergo EU joint clinical assessments announced
IRA holds the scope to shape pharma’s research strategy, say experts
International Reference Pricing (IRP) 2024: A year in review
